Pharma Industry

Industry: Email Alert RSS Feed

Prospective study using remicade in psoriasis patients with an inadequate response to etanercept

Journal of Drugs in Dermatology, March, 2008

Sponsored by: Centocor, Inc. The purpose of this study is to test the safety and effectiveness of infliximab in patients with plaque psoriasis who have been receiving the drug etanercept for treatment of their plaque psoriasis for at least 4 months, without enough improvement in their psoriasis symptoms.

Condition  Intervention            Phase

Psoriasis  Biological: infliximab  Phase III

Study ID Numbers: CR014500, C0168Z04

Most RecentPharma Articles

ClinicalTrials.gov Identifier: NCT00527072

COPYRIGHT 2008 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2008 Gale, Cengage Learning

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:
  1. You are currently: a Guest |
  4.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement

Brought to you by CBS MoneyWatch.com

advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here

Content provided in partnership with Thompson Gale